Highest-materiality recent filing
Abbott adds Kevin Conroy to board; shareholders approve 2026 Incentive Stock Program
Kevin Conroy appointed to Abbott's Board of Directors effective April 24, 2026.
Settlement of consolidated derivative action alleging fiduciary breaches and securities violations related to infant formula recall.
Abbott Q1 adj. EPS $1.15, +6% YoY; acquires Exact Sciences; FY guidance $5.38-$5.58
Q1 GAAP diluted EPS $0.61; adjusted diluted EPS $1.15 (+6% YoY).
Abbott completes $105/share cash acquisition of Exact Sciences, expanding cancer diagnostics
Abbott completed acquisition of Exact Sciences for $105/share cash; Exact becomes wholly owned subsidiary.
Abbott completes $20B senior notes offering to fund Exact Sciences acquisition
Issued $20B in eight tranches: Floating Rate Notes due 2029, fixed-rate notes from 3.700% to 5.600% with maturities 2029–2066.
Abbott issues $20B multi-tranche notes; proceeds to fund Exact Sciences acquisition
Issued $20B in senior notes across 8 tranches: floating and fixed rates from 3.70% to 5.60%, maturities 2029-2066.
Abbott reduces board size from 13 to 12 directors effective April 24, 2026
Board of Directors amended Article III, Section 2 of By-Laws on February 20, 2026.
Abbott Q4 adj EPS $1.50 (+12% YoY); FY2025 revenue $44.3B; FY2026 adj EPS guide $5.55–$5.80
Q4 GAAP EPS $1.01, adjusted EPS $1.50 (+12% YoY); revenue $11.46B (+4.4% reported, +3.8% ex-COVID).
Abbott names Nita Ahuja to Board of Directors; board expands to 13 members
Nita Ahuja, M.D. appointed to Abbott’s Board of Directors effective December 12, 2025.
Abbott blackout period for retirement plan Dec 24 to Jan 11 due to admin changes
Blackout begins Dec 24, 2025 at 12pm CST, ends week of Jan 11, 2026.
Abbott to acquire Exact Sciences for $105/share, total equity value ~$21B
Abbot buys Exact Sciences for $105 per share in cash; equity value ~$21B, enterprise value ~$23B.
Abbott Q3 sales rise 6.9%; adj. EPS $1.30; reaffirms FY guidance
GAAP diluted EPS $0.94; adjusted diluted EPS $1.30; reported sales $11.37B, organic growth 5.5% (7.5% ex-COVID testing).
Abbott Q2 adjusted EPS $1.26, sales $11.14B (+7.4%); guides FY adjusted EPS $5.10-$5.20
GAAP diluted EPS $1.01; adjusted diluted EPS $1.26, double-digit growth YoY.
Abbott General Counsel Hubert L. Allen to retire after transition period
Hubert L. Allen, EVP, General Counsel and Secretary, notified Abbott on April 25, 2025 of his planned retirement.
Abbott annual meeting results: all directors elected, auditor ratified, say-on-pay approved
All 12 director nominees elected; Nancy McKinstry received 1.12B for vs 243.9M against (82%).
Abbott Q1 adjusted EPS $1.09, revenue $10.36B (+4% reported); reaffirms FY guidance
GAAP diluted EPS $0.76; adjusted diluted EPS $1.09 (double-digit YoY growth).
Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25
Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.
Abbott extends change-in-control agreements for NEOs through Dec 2026
Agreements previously set to expire Dec 31, 2024, now extended to Dec 31, 2026.
Abbott Q3 2024: GAAP EPS $0.94, adj. EPS $1.21; raises FY adj. EPS guidance midpoint
Reported sales $10.6B (+4.9% reported, +8.2% organic ex-COVID tests); Medical Devices +13.3% organic.
Abbott Q2 adjusted EPS $1.14, revenue $10.4B; raises FY guidance
GAAP EPS $0.74, adjusted $1.14; revenue $10.4B (+4% reported, +9.3% organic ex-COVID).
Abbott EVP Finance Robert Funck Jr. to retire July 1, 2024 after 36 years
Robert E. Funck Jr., Executive Vice President, Finance, plans to retire effective July 1, 2024.
Abbott annual meeting results elect board, ratify auditor, approve executive compensation
All 12 board nominees elected; Nancy McKinstry received ~242.6M against votes, John G. Stratton ~347.3M against.
On April 25, 2025, Hubert L. Allen, Executive Vice President, General Counsel and Secretary, informed Abbott Laboratories that he plans to retire from the company after a period of transition.
Robert E. Funck, Jr., Executive Vice President, Finance, informed Abbott Laboratories that he plans to retire from the company after 36 years of service, effective July 1, 2024.
Max materiality 1.00 · Median 0.72 · Most common event earnings